Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan

Archives of Gerontology and Geriatrics

Volumn 49, Issue SUPPL.2, 2009, Pages

  Chou, Yin Yi ^a   Sheu, Wayne H H ^a,d   Tang, Yih Jing ^a   Chen, Yi Ming ^a,b   Liao, Szu Chia ^a   Chuang, Ya Wen ^a   Lin, Chu Sheng ^a   Chen, Der Yuan ^a,b,c,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Institutionalized elderly residents; Metabolic syndrome (MS); Plasminogen activator inhibitor type 1 (PAI 1)

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BODY FAT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPEDANCE; INFLAMMATION; INSTITUTIONAL CARE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RESIDENTIAL HOME; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HOMES FOR THE AGED; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NURSING HOMES; PLASMINOGEN ACTIVATOR INHIBITOR 1; TAIWAN; TUMOR NECROSIS FACTOR-ALPHA; VETERANS; WAIST CIRCUMFERENCE;

EID: 71849120421     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4943(09)70012-3     Document Type: Article

References (33)

1. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., Kim N.H., Choi D.S., and Baik S.H. Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res. Clin. Pract. 64 (2004) 99-106
2. Collet J.P., Montalescot G., Vicaut E., Ankri A., Walylo F., Lesty C., Choussat R., Beygui F., Borentain M., Vignolles N., and Thomas D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108 (2003) 391-394
3. Cornier M.A., Dabelea D., Hernandez T.L., Lindstrom R.C., Steig A.J., Stob N.R., Van Pelt R.E., Wang H., and Eckel R.H. The metabolic syndrome. Endocr. Rev. 29 (2008) 777-822
4. Despres J.P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9 (1993) 452-459
5. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
6. Executive Summary. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285 (2001) 2486-2497
7. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 102 (2002) 42-47
8. Goral J. TNF-alpha and carbohydrate and lipid parameters in overweight and obese children. Ann. Acad. Med. Stetin. 54 (2008) 14-21
9. Henry M., Tregouet D.A., Alessi M.C., Aillaud M.F., Visvikis S., Siest G., Tiret L., and Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 84-91
10. Hoekstra T., Geleijnse J.M., Schouten E.G., Kok F.J., and Kluft C. Relationship of C-reactive protein with components of the metabolic syndrome in normal-weight and overweight elderly. Nutr. Metab. Cardiovasc. Dis. 15 (2005) 270-278
11. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271 (1996) 665-668
12. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., and Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med. 164 (2004) 1066-1076
13. Jiamsripong P., Mookadam M., Honda T., Khandheria B.K., and Mookadam F. The metabolic syndrome and cardiovascular disease: Part I. Prev. Cardiol. 11 (2008) 155-161
14. Juhan-Vague I., Roul C., Alessi M.C., Ardissone J.P., Heim M., and Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients-relationship with plasma insulin. Thromb. Haemostasis 61 (1989) 370-373
15. Juhan-Vague I., Alessi M.C., and Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 58 Suppl. 1 (1991) 19-20
16. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94 (1996) 2057-2063
17. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost. 1 (2003) 1575-1579
18. Kahn S.E., Prigeon R.L., Schwartz R.S., Fujimoto W.Y., Knopp R.H., Brunzell J.D., and Porte Jr. D. Obesity, body fat distribution, insulin sensitivity and Islet B-cell function as explanations for metabolic diversity. J. Nutr. 131 (2001) 354-360
19. Kruszynska Y.T., Yu J.G., Olefsky J.M., and Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49 (2000) 633-639
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Popa C., Netea M.G., Van Riel P.L., Van der Meer J.W., and Stalenhoef A.F. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 48 (2007) 751-762
22. Potter van Loon B.J., Kluft C., Radder J.K., Blankenstein M.A., and Meinders A.E. The cardiovascular risk factor plasminogen activator inhibitor Type 1 is related to insulin resistance. Metabolism 42 (1993) 945-949
23. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14 (1998) 263-283
24. Sam S., Haffner S., Davidson M.H., D'Agostino Sr. R.B., Feinstein S., Kondos G., Perez A., and Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 32 (2009) 932-937
25. Samad F., and Loskutoff D.J. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol. Med. 2 (1996) 568-582
26. Tan C.E., Ma S., Wai D., Chew S.K., and Tai E.S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?. Diabetes Care. 27 (2004) 1182-1186
27. Torres J.L., and Ridker P.M. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr. Opin. Cardiol. 18 (2003) 471-478
28. Trost S., Pratley R., and Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type II diabetes. Curr. Diab. Rep. 6 (2006) 47-54
29. Vague P., Juhan-Vague I., Aillaud M.F., Badier C., Viard R., Alessi M.C., and Collen D. Correlation between blood fibrinolytic activity, PA-inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 35 (1986) 250-253
30. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. J. Am. Med. Assoc. 282 (1999) 2131-2135
31. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-I10
32. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., and Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112 (2005) 3066-3072
33. You T., Nicklas B.J., Ding J., Penninx B.W., Goodpaster B.H., Bauer D.C., Tylavsky F.A., Harris T.B., and Kritchevsky S.B. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J. Gerontol. A. Biol. Sci. Med. Sci. 63 (2008) 414-419